| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Faisal Hakami, Essam Alhazmi, Wafa M Busayli, Sultan Althurwi, Abdulrahman M Darraj, Mohammed A Alamir, Alyaj Hakami, Renad A Othman, Amal I Moafa, Hassan A Mahasi, Mohammed Ali Madkhal. Overview of the Association Between the Pathophysiology, Types, and Management of Sickle Cell Disease and Stroke. Cureus. vol 15. issue 12. 2023-12-19. PMID:38107212. |
this review examines the pathophysiological association between scd and stroke, the classification of stroke types, risk factors, diagnosis, management, prevention, and prognosis. |
2023-12-19 |
2023-12-21 |
Not clear |
| Faisal Hakami, Essam Alhazmi, Wafa M Busayli, Sultan Althurwi, Abdulrahman M Darraj, Mohammed A Alamir, Alyaj Hakami, Renad A Othman, Amal I Moafa, Hassan A Mahasi, Mohammed Ali Madkhal. Overview of the Association Between the Pathophysiology, Types, and Management of Sickle Cell Disease and Stroke. Cureus. vol 15. issue 12. 2023-12-19. PMID:38107212. |
relevant studies on scd and stroke pathophysiology, classification, epidemiology, diagnosis, treatment, and prevention were identified. |
2023-12-19 |
2023-12-21 |
Not clear |
| Faisal Hakami, Essam Alhazmi, Wafa M Busayli, Sultan Althurwi, Abdulrahman M Darraj, Mohammed A Alamir, Alyaj Hakami, Renad A Othman, Amal I Moafa, Hassan A Mahasi, Mohammed Ali Madkhal. Overview of the Association Between the Pathophysiology, Types, and Management of Sickle Cell Disease and Stroke. Cureus. vol 15. issue 12. 2023-12-19. PMID:38107212. |
this review synthesizes current evidence on scd and stroke to highlight opportunities for further research and standardizing care protocols across institutions. |
2023-12-19 |
2023-12-21 |
Not clear |
| Adetola A Kassim, Michael R DeBau. The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally. Hematology. American Society of Hematology. Education Program. vol 2023. issue 1. 2023-12-09. PMID:38066894. |
the ideal curative therapy for sickle cell disease (scd) must be applicable across all ages and include individuals with strokes and preexisting heart, lung, and kidney disease. |
2023-12-09 |
2023-12-17 |
human |
| Abdalla M Zayed, Sulaiman Al-Muhaimeed, Turki Al-Otaibi, Elsayed Mohammed Ali, Rashid Saleh, Shangrila Joy Ancheta, Fahad Al-Harbi, Khawaja Bilal Waheed, Yasir Albahli, Hamid Alghamd. Moyamoya Syndrome in Children With Sickle Cell Disease in Saudi Arabia: A Single-Center Experience. Cureus. vol 15. issue 11. 2023-12-01. PMID:38024048. |
the target population was children aged six months to 14 years with scd and a history of stroke or transient ischemic attacks (tias). |
2023-12-01 |
2023-12-07 |
Not clear |
| Abdalla M Zayed, Sulaiman Al-Muhaimeed, Turki Al-Otaibi, Elsayed Mohammed Ali, Rashid Saleh, Shangrila Joy Ancheta, Fahad Al-Harbi, Khawaja Bilal Waheed, Yasir Albahli, Hamid Alghamd. Moyamoya Syndrome in Children With Sickle Cell Disease in Saudi Arabia: A Single-Center Experience. Cureus. vol 15. issue 11. 2023-12-01. PMID:38024048. |
conclusion in this study, the prevalence of overt stroke is 9% in children with scd originating from the southwestern region of saudi arabia (26/286), and 61.5% of them (16/26) had mms. |
2023-12-01 |
2023-12-07 |
Not clear |
| Abdalla M Zayed, Sulaiman Al-Muhaimeed, Turki Al-Otaibi, Elsayed Mohammed Ali, Rashid Saleh, Shangrila Joy Ancheta, Fahad Al-Harbi, Khawaja Bilal Waheed, Yasir Albahli, Hamid Alghamd. Moyamoya Syndrome in Children With Sickle Cell Disease in Saudi Arabia: A Single-Center Experience. Cureus. vol 15. issue 11. 2023-12-01. PMID:38024048. |
in places lacking tcd facilities, further studies are required to determine if mra brain screenings of children with scd may detect mms before the onset of stroke and help start protective therapy. |
2023-12-01 |
2023-12-07 |
Not clear |
| Abdalla M Zayed, Sulaiman Al-Muhaimeed, Turki Al-Otaibi, Elsayed Mohammed Ali, Rashid Saleh, Shangrila Joy Ancheta, Fahad Al-Harbi, Khawaja Bilal Waheed, Yasir Albahli, Hamid Alghamd. Moyamoya Syndrome in Children With Sickle Cell Disease in Saudi Arabia: A Single-Center Experience. Cureus. vol 15. issue 11. 2023-12-01. PMID:38024048. |
the target population was children aged six months to 14 years with scd and a history of stroke or transient ischemic attacks (tias). |
2023-11-29 |
2023-12-07 |
Not clear |
| Abdalla M Zayed, Sulaiman Al-Muhaimeed, Turki Al-Otaibi, Elsayed Mohammed Ali, Rashid Saleh, Shangrila Joy Ancheta, Fahad Al-Harbi, Khawaja Bilal Waheed, Yasir Albahli, Hamid Alghamd. Moyamoya Syndrome in Children With Sickle Cell Disease in Saudi Arabia: A Single-Center Experience. Cureus. vol 15. issue 11. 2023-12-01. PMID:38024048. |
conclusion in this study, the prevalence of overt stroke is 9% in children with scd originating from the southwestern region of saudi arabia (26/286), and 61.5% of them (16/26) had mms. |
2023-11-29 |
2023-12-07 |
Not clear |
| Abdalla M Zayed, Sulaiman Al-Muhaimeed, Turki Al-Otaibi, Elsayed Mohammed Ali, Rashid Saleh, Shangrila Joy Ancheta, Fahad Al-Harbi, Khawaja Bilal Waheed, Yasir Albahli, Hamid Alghamd. Moyamoya Syndrome in Children With Sickle Cell Disease in Saudi Arabia: A Single-Center Experience. Cureus. vol 15. issue 11. 2023-12-01. PMID:38024048. |
in places lacking tcd facilities, further studies are required to determine if mra brain screenings of children with scd may detect mms before the onset of stroke and help start protective therapy. |
2023-11-29 |
2023-12-07 |
Not clear |
| Marina García-Morin, Eduardo J Bardón-Cancho, Cristina Beléndez, Elena Dulín, Paula Blanco-Soto, Carolina Puertas-López, Mar Prieto-Medina, Áurea Cervera-Bravo, Lucía Llorente-Otones, Vanesa Pérez-Alonso, Sonsoles San-Román, Cruz Vecilla-Rivelles, Montserrat López-Rubio, Elena Sebastián, José M Bellón, Elena Cel. Madrid Newborn Sickle Cell Disease Cohort: clinical outcomes, stroke prevention and survival. Annals of hematology. 2023-11-18. PMID:37980280. |
the aim of this study is to describe the morbimortality and the stroke prevention programme in patients diagnosed by scd nbs in madrid. |
2023-11-18 |
2023-11-20 |
Not clear |
| Helen Fogarty, Azaz Ahmad, Ferdows Atiq, Dearbhla Doherty, Soracha Ward, Ellie Karampini, Aisling M Rehill, Gemma Leon, Ciara Byrne, Rosena Geoghegan, Helena Conroy, Mary B Byrne, Ulrich Budde, Sonja Schneppenheim, Ciara Sheehan, Noel Ngwenya, Ross Ian Baker, Roger J S Preston, Emma Tuohy, Corrina B McMahon, James S O'Donnel. VWF-ADAMTS13 axis dysfunction in children with sickle cell disease treated with hydroxyurea versus blood transfusion. Blood advances. 2023-09-29. PMID:37773926. |
although blood transfusion is the gold standard for stroke prevention in scd, the biological mechanisms underpinning its improved efficacy compared to hydroxycarbamide are not fully understood. |
2023-09-29 |
2023-10-07 |
Not clear |
| Kristine A Karkoska, Jahnavi Gollamudi, Hyacinth I Hyacint. Molecular and environmental contributors to neurological complications in sickle cell disease. Experimental biology and medicine (Maywood, N.J.). 2023-09-09. PMID:37688519. |
the neurological complications of scd are particularly devastating and diverse, ranging from overt stroke to covert cerebral injury, including silent cerebral infarctions and blood vessel tortuosity. |
2023-09-09 |
2023-10-07 |
Not clear |
| Salman J Khan, Syed Asjad Tauheed Zaidi, Syeda Fatima Murtaza, Muhammad Asif, Vinod Kuma. Advancements in Sickle Cell Disease (SCD) Treatment: A Review of Novel Pharmacotherapies and Their Impact on Patient Outcomes. Cureus. vol 15. issue 8. 2023-09-04. PMID:37664319. |
patients with scd experience a broad range of symptoms ranging from anemia, pain crises, and jaundice to acute coronary syndrome and stroke. |
2023-09-04 |
2023-09-07 |
Not clear |
| Ghidaa Babeer, Danah Omran, Noor Bawahab, Raghad W Mohammed Hussain, Osama Muthaffar, Fatmah Alzahrani, Jumana A Shafe. Prevalence and Risk Factors of Stroke Among Children With Sickle Cell Disease: A Retrospective Study at a Tertiary Care Center. Cureus. vol 15. issue 7. 2023-08-17. PMID:37588307. |
previous history of stroke, high mean corpuscular volume (mcv), and low red blood cells count (rbc) were statistically significant risk factors for stroke (p<0.0001), (p<0.0001), (p<0.03), respectively. conclusion stroke is one of the most devastating complications of scd. |
2023-08-17 |
2023-09-07 |
Not clear |
| Ghidaa Babeer, Danah Omran, Noor Bawahab, Raghad W Mohammed Hussain, Osama Muthaffar, Fatmah Alzahrani, Jumana A Shafe. Prevalence and Risk Factors of Stroke Among Children With Sickle Cell Disease: A Retrospective Study at a Tertiary Care Center. Cureus. vol 15. issue 7. 2023-08-17. PMID:37588307. |
the prevalence of stroke among scd patients in our study was 16%. |
2023-08-17 |
2023-09-07 |
Not clear |
| Jihee Choi, John Emmanuel Markantonis, Nicole De Simone, Alecia Nero, Jaehyup Kim, Ravi Sarod. Hemoglobin S target of <50% as compared to 30% in chronic red cell exchange for secondary stroke prevention in sickle cell disease. Journal of clinical apheresis. 2023-08-01. PMID:37525930. |
sickle cell disease (scd) patients with a history of stroke are encouraged to receive chronic red blood cell exchange (rbcx) for stroke prevention. |
2023-08-01 |
2023-08-14 |
Not clear |
| Nirupama Ramadas, Erica M Sparkenbaug. The APC-EPCR-PAR1 axis in sickle cell disease. Frontiers in medicine. vol 10. 2023-07-27. PMID:37497271. |
the two predominant pathologies of scd are hemolytic anemia and vaso-occlusive episodes (voe), along with sequelae of complications including acute chest syndrome, hepatopathy, nephropathy, pulmonary hypertension, venous thromboembolism, and stroke. |
2023-07-27 |
2023-08-14 |
Not clear |
| Giulia Reggiani, Beatrice Coppadoro, Vania Munaretto, Alessio Pieroni, Federica Viaro, Renzo Manara, Anne Beaubrun, Alessandra Biffi, Claudio Baracchini, Laura Sainati, Raffaella Colombatt. Relationship between hemoglobin, hemolysis, and transcranial Doppler velocities in children with sickle cell disease: Results from a long-term natural history study in Italy in the era of multimodal therapy. European journal of haematology. 2023-06-07. PMID:37282348. |
stroke and cerebral vasculopathy are leading causes of morbidity and mortality in patients with sickle cell disease (scd). |
2023-06-07 |
2023-08-14 |
Not clear |
| Ding Wen Wu, Jessica Jacobson, Mark Lifshitz, Yanhua Li, Chen Lyu, Rachel Friedmann, Ronald Walsh, Evan Himchak, Kala Mohandas, Sadiqa Karim, Etan Marks, Sang Hwa Himchak, Timothy Hilber. A retrospective study for association between post-transfusion hemoglobin S level and pre-transfusion hemoglobin S level at the next scheduled transfusion. Journal of clinical apheresis. 2023-05-18. PMID:37198953. |
patients with sickle cell disease (scd) frequently undergo prophylactic red blood cell (rbc) exchange transfusion and simple transfusion (rce/t) to prevent complications of disease, such as stroke. |
2023-05-18 |
2023-08-14 |
Not clear |